Drug-Eluting Stent

A registry of drug-eluting devices for the treatment of patients with peripheral arterial disease is meeting its enrollment goals for women and patients from historically underrepresented backgrounds, researchers reported at VIVA 22.

Long-term P2Y12 inhibition after PCI reduced bleeding at 3 years compared with dual antiplatelet therapy, with no significant differences observed for ischemic events, according to new data from the SMART-CHOICE trial.

BOSTON — After 2 years, PCI with amphilimus-eluting stents was noninferior to PCI with zotarolimus-eluting stents in patients with diabetes, not confirming the potential superiority signal observed at 1 year.

Medtronic announced it received FDA approval for its provisional bifurcation stenting technique utilizing a single drug-eluting stent for non-left main bifurcation lesions.

Abbott announced it received FDA approval, CE mark approval in Europe, and Pharmaceuticals and Medical Devices Agency approval in Japan, and has launched new 4.5 mm and 5 mm stent sizes.

Prespecified, real-world study assessing long-term safety of paclitaxel-coated devices vs. non-paclitaxel-coated devices for femoropopliteal artery revascularization in PAD.

Safety and efficacy at 5 years with Orsiro Sirolimus Eluting vs. Xience coronary stent systems in up to three native de novo or restenotic coronary artery lesions.

A novel drug-eluting coronary artery implant that “uncages” after 6 months appears to have similar short-term performance to a drug-eluting stent while maintaining flexibility of the treated artery, according to an early study in humans.

ATLANTA — An analysis of 160,000 Medicare beneficiaries demonstrated the noninferiority of paclitaxel-coated devices for mortality compared with uncoated devices for the treatment of peripheral artery disease, a speaker reported.

In patients with high bleeding risk who underwent complex PCI, dual antiplatelet therapy for approximately 1 month reduced bleeding compared with slightly longer DAPT duration, according to new data from the MASTER DAPT trial.